anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a skin-care sunblock product for infants. The skin-care sunblock product comprises an A phase, a B phase, a C phase and a D phase. The A phase is composed of cetostearyl alcohol olive oil acid ester, cetostearyl alcohol, glyceryl stearate, squalane, simmondsia chinensis seed oil, isohexadecane, nano-zinc oxide, ethylhexyl methoxycinnamate and polydimethylsiloxane. The B phase is composed of water, glycerol, 1,3-propylene glycol, butanediol and EDTA disodium. The C phase is emulgator polyacrylate-13, polyisobutene and polysorbate-20. The D phase is composed of vitamin E, phenoxyethanol, 1,2-octylene glycol and plant desensitizer. The skin-care sunblock product for infants is capable of protecting the delicate skin of the infants and protecting the infants against sunburn, good in moisturizing effect, safer and healthier.
Written Exposure Therapy (WET) plus Treatment As Usual (TAU). WET is a 5 session, evidence-based trauma-focused written narrative exposure treatment. At each session, patients are instructed to write about the same trauma event and therapists provide feedback about adherence and offer suggestions. The first session includes psychoeducation about PTSD and a treatment rationale prior to general trauma narrative writing instructions, and specific instructions for completing the first writing session, before completing the first writing (30 minutes) session. Participants are instructed to write about the same trauma event at each following session, with an emphasis on delving into their deepest emotions and thoughts, in as much detail as possible, about the event. All writing sessions begin with specific instructions from the therapist followed by 30 minutes of writing by the participant.
Patients have been consecutively screened at admission by SGA (Subjective-Global-Assessment)-Score and NRS 2002 (Nutritional-Risk-Screening)-Score in the departments of surgery and internal medicine. The nutrition status of each patient is combined with clinical data, utilization data and direct costs on the basis of clinical homogenous patient clusters. Risk-Adjustment was provided by the Disease-Staging-Scale (MEDSTAT/Thomson Healthcare, Ann Arbor MI), which allows patient classification by diagnosis and co morbidities including age and gender. The risk adjustment scales run by routine data sets from german inpatient G-DRG system. In the control period the effects of usual nutrition care are documented. During the intervention period an implementation of an interdisciplinary evidence-based guideline for screening and clinical nutrition was introduced in each participating hospital.

The issue is to describe the relation between risk-adjusted malnutrition status and clinical outcomes and costs.
A cosmetic liner, such as a lip liner, containing a tanning composition comprising at least one tanning component capable of reacting with human skin to provide a more tanned appearance and a dermatologically acceptable carrier. The tanning component is preferably a polyhydroxy-ketone capable of undergoing a Maillard reaction with amino acids in skin keratin, particularly dihydroxyacetone (DHA) or erythrulose or a mixture thereof. The carrier may be aqueous, and may further comprise polyols selected from propylene glycol, butylene glycol and mixtures thereof. The composition may comprise a preservative selected from phenoxyethanol. The liner may further comprise one or more substances selected from parfum, tocopheryl acetate, coumarin, citric acid, aloe barbadensis powder, EDTA salts such as tetrasodium EDTA, and colourings. The cosmetic liner may comprise a reservoir for the tanning composition and wick which extends from the reservoir to a nib of the liner. A method of tanning the lips using the liner is also provided.
High-protein (1.2-1.5 g protein per kg bodyweight; a milk-based protein drink will provide 50 g protein/day) energy-restricted (500 kcal deficit) diet and a multimodal exercise program (balance, flexibility, aerobic, resistance) 3 times/week, each lasting 1 hour. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
A physical therapist performance a simulated manipulation intervention, for which the same position as in the Intervention Group will be used, in right lateral decubitus with the left leg flexed and the left foot resting on the right popliteal fossa. Without stretching the paravertebral tissues, the participant will remain for approximately 20 seconds without receiving manual impulse.
The present disclosure provides an improved peptide tag moiety, with affinity for a binding molecule. The peptide tag moiety is for example useful as a part of a tag construct, e.g., together with a cargo moiety. It exhibits unexpected benefits as part of a biopharmaceutical product complex, when compared to known tag moieties having a similar amino acid sequence. Also disclosed are binding molecules and bispecific conjugates with affinity for the peptide tag moiety, and complexes comprising the peptide tag moiety non-covalently bound to a such binding molecules or bispecific conjugates. In such complexes, the tag moiety may for example form part of a tag construct further comprising an antigen as cargo moiety, for antigen delivery to immune cells. Medical uses of the tag moiety, tag construct and complex of the disclosure are also provided.
NEW MATERIAL:A substance bonded with immunoglobulin, IBS-I [elementary analysis, C 38.32, H 5.38, N 19.38; molecular weight, 25,000-30,000 dalton (high- speed liquid chromatography); solubility, easily soluble in water and insoluble in methanol, ethanol, benzene, etc.; pH of the aqueous solution, nearly neutral; amino acid composition, as shown in Table I ] and IBS-II. USE:An immunoadsorbent. It has nonspecific bonding activity to immunoglobulin. PROCESS:Ground grain weevil is defatted with fat-soluble organic solvent, and the residue is extracted with an aqueous solvent. The extract is subjected to the affinity chromatography using a polysaccharide bonded with immonoglobulin and to the gel filtration, and the objective IBS- I and/or IBS-II are separated from the fractions containing IBS- I and/or IBS-II.
PROBLEM TO BE SOLVED: To obtain a makeup composition capable of dissolving a peroxidized sebum blocking hair bulbs and accelerating blood circulation of the scalp by making the composition include an extract solution of loess, an extract solution of brown algae, an extract solution of a mugwort, an extract solution of a pine needle and an additive therein. SOLUTION: This composition is obtained by including (A) an extract solution of loess containing various inorganic substances such as silicon dioxide, aluminum and magnesium, (B) an extract solution of brown algae extracted from a sea mutard (Undaria pinnatifida Suringar) and a sea tangle and containing calcium, iodine and various inorganic substances, (C) an extract solution of a mugwort containing a cineole and a sesquiterpene ingredients, (D) an extract solution of a pine needle containing a protein, a lipid, a glucide, cellulose, an ash, calcium, phosphorus, iron and vitamins, etc., and (E) an additive. In the composition, the ingredient A in an amount of about 50 pts.wt., the ingredient B in an amount of about 50 pts.wt. and the ingredient D in an amount of about 20 pts.wt. based on 10 pts.wt. ingredient C are preferably contained.
A method and automated system for processing blood in which the automated system includes a programmable controller, a database, and an interactive display screen for displaying information and receiving operator input. The programmable controller is configured to automatically control the system to perform the method. Upon activation of the system, the screen displays a listing of different blood processing procedures that may be performed using the system. The operator may then input into the controller an identification of a specified blood processing procedure that is to be performed, such that an initial list of parameters that are associated with the specified blood processing procedure are displayed on the screen. The operator may then input into the controller an identification of the parameters that are to populate the display screen during performance of the procedure and indicate a format in which the selected parameters are to be presented on the display screen. The controller then creates a display for the specified blood processing procedure. Current values of the selected parameters in the selected format are displayed on the screen during performance of the specified procedure. The controller automatically saves an image of the display screen periodically during performance of the specified blood processing procedure, and transfers information from the saved images of the display screens to a procedure record form.
PURPOSE:To produce the titled composition useful for the prevention of periodontosis, by using the whole cell, pilus or capsule of bacterial causing periodontosis as an antigen, immunizing a mammal with the antigen, using the resultant antigen as an active component and adding a synergist component thereto. CONSTITUTION:The cell, pilus or capsule of bacterial causing periodontosis (e.g. Gram-negative bacteria in oral cavity such as Bacteroides gingivalis, Gram- positive bacteria such as Actinomyces viscosus, etc.) is used as an antigen. The antibody produced by immunizing a mammal with the above antigen is compounded with one or more synergists selected from chlorhexidines, bacteriosin, bacteriolytic enzyme, protease and dextranase. The fixing of the periodontosis-causing bacteria in oral cavity can be prevented effectively by the compounded composition. Accordingly, the agent enables the effective prevention of periodontosis such as periodontotis and has high safety. Dose: preferably 0.0001-50g of the antibody per kg daily.
PrEP is a critical component of comprehensive transgender medical care. The proposed open-label, intensive PK study will inform the pharmacologic impact of combining PrEP and concurrent feminizing hormone regimens. The investigators hypothesize transgender women will achieve similar PrEP concentrations compared to the historical controls, and that hormone concentrations (estrogen and testosterone) will not be affected. The aims of this study are to (1) to determine if concurrent use of TDF/FTC as PrEP in combination with feminizing hormones alters the PK of tenofovir (TFV) and FTC and (2) to determine if concurrent use of PrEP with feminizing hormones alters serum estradiol and testosterone concentrations. To achieve these aims, this study will enroll transgender women who are receiving either oral/sublingual or transdermal estradiol with spironolactone. Using intensive PK sampling, plasma and intracellular TDF/FTC concentrations will be measured after 14 days of oral TDF/FTC.
The present invention discloses an antipyretic granular preparation containing cassia twig, ephedra and bupleurum root, and a preparing technology thereof. The antipyretic granular preparation has the special effect on a patient with cold and fever which are not cured for a long time. By taking the antipyretic granular preparation, the symptoms of cold and fever which are not cured for a long time, or lasting fever caused by uncertain reasons are treated. The antipyretic granular preparation of the present invention has the characteristics of wide indication, quick defervescence function, no relapse after cure, etc. The prescription of the antipyretic granular preparation comprises main medicinal materials and auxiliary medicinal materials, wherein the main medicinal materials comprise cassia twig, ephedra, bupleurum root, radix paeoniae alba, baical skullcap root and gypsum; the auxiliary medicinal materials comprise rhizoma anemarrhenae, monkshood, codonopsis pilosula, liquorice root, ginger and Chinese date. The technology comprises: boiling in water for three times; extracting medicine liquid after filtration; heating the medicine liquid for evaporating water; preparing extract; adding sugar powder, maize starch or dextrin, etc.; manufacturing granules with a machine; packing the granules in a plastic bag after drying the whole granules.
Nueva Vida Intervention consists of 8 sessions of a skills-building group held twice a month for 4 months. Latina survivors and their caregivers arrive at the group together, separate into different rooms to learn the coping and communication skills, and then join together for discussion of the topic.
Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing relapse after previously achieving CR may receive additional tipifarnib at the current dose level for newly registered patients.
PURPOSE:To specify the addition, subtraction or non-totalization of nutritive value data in a classification/totalization storage part in accordance with the operation of an input key at the classification/totalization of the nutritive values of real intakes calculated by an operating means in a caloric intake meter. CONSTITUTION:The quantity of respective components and the unit level of energy per unit weight of each food shown in a food exchange table are stored in a food component storage part 8. When a food No. individually assigned to each food is inputted from a data input part 26, the data of the corresponding food are stored in a register 9 and specification levels instructed by a doctor are stored in a storage part 10 by sorting these levels into each classified list of the food exchange table and respective components such as energy, protein, lipid, and salt. The intakes of respective components calculated from foods taken by the user can be calculated and stored in th classification/totalization storage part 13. In this case, any operation out of addition, subtraction or no input is executed in accordance with each key operation of [+ intake key] 26j, [- intake key] 26l or [non-operation key] 26k while observing the display of the operated result.
BACKGROUND: This study aimed to assess the early- and mid-term outcomes of aortic root repair and replacement, and to provide evidence to improve root management in acute type A aortic dissection (AAAD).
METHODS: This study enrolled 455 patients who underwent AAAD root repair (n = 307) or replacement (n = 148) between January 2016 and December 2017. Inverse probability of treatment weighting (IPTW) method was used to control for treatment selection bias. The primary outcomes were in-hospital mortality, mid-term survival, and proximal aortic reintervention.
RESULTS: The success rate of root repair was 99.7%. The in-hospital mortality in the conservative root repair (CRR) and aggressive root replacement (ARR) were 8.1% and 10.8%. The median follow-up time was 67.76 months (IQR, 67-72 months). After adjusting for baseline factors, there was no significant differences in mid-term survival (p = .750) or the proximal aortic reintervention rate (p = .550) between the two groups. According to Cox analysis, age, hypertension, severe aortic regurgitation, CPB time, and concomitant CABG were all factors associated with mid-term mortality. Regarding reintervention, multivariate analysis identified renal insufficiency, bicuspid aortic valve, root diameter ≥ 45 mm, and severe aortic regurgitation as risk factors, while CRR did not increase the risk of reintervention. The subgroup analysis revealed heterogeneity in the effects of surgical treatment across diverse populations based on a variety of risk factors.
CONCLUSIONS: For patients with AAAD, both CRR and ARR are appropriate operations with promising early and mid-term outcomes. The effects of treatment show heterogeneity across diverse populations based on various risk factors.
Not for injection.

Solutions for urologic irrigation must be used with caution in patients with severe cardiopulmonary or renal dysfunction.

Irrigating fluids used during transurethral prostatectomy have been demonstrated to enter the systemic circulation in relatively large volumes; thus 1.5% Glycine Irrigation, USP must be regarded as a systemic drug. Absorption of large amounts of fluids containing glycine may significantly alter cardiopulmonary and renal dynamics.

Careful cardiovascular monitoring should be maintained due to the possibility of fluid overload. Should fluid overload occur, intensive fluid and electrolyte management is necessary. Monitoring of fluid and electrolyte levels beyond the acute phase may be considered due to the possibility of delayed fluid absorption. (See ADVERSE REACTIONS, Post-Marketing Experience).

The contents of an opened container should be used promptly to minimize the possibility of bacterial growth or pyrogen formation. Discard the unused portion of irrigating solution since no antimicrobial agent has been added.
Innate immune training involves myelopoiesis, dynamic gene modulation, and functional reprogramming of myeloid cells in response to secondary heterologous challenges. The present study evaluates whether systemic innate immune training can protect tissues from local injury. Systemic pretreatment of mice with β-glucan, a trained immunity agonist, reduces the mortality rate of mice with bleomycin-induced lung injury and fibrosis, as well as decreasing collagen deposition in the lungs. β-Glucan pretreatment induces neutrophil accumulation in the lungs and enhances efferocytosis. Training of mice with β-glucan results in histone modification in both alveolar macrophages (AMs) and neighboring lung epithelial cells. Training also increases the production of RvD1 and soluble mediators by AMs and efferocytes. Efferocytosis increases trained immunity in AMs by stimulating RvD1 release, thus inducing SIRT1 expression in neighboring lung epithelial cells. Elevated epithelial SIRT1 expression is associated with decreased epithelial cell apoptosis after lung injury, attenuating tissue damage. Further, neutrophil depletion dampens the effects of β-glucan on macrophage accumulation, epigenetic modification in lung macrophages, epithelial SIRT1 expression, and injury-mediated fibrosis in the lung. These findings provide mechanistic insights into innate immune training and clues to the potential ability of centrally trained immunity to protect peripheral organs against injury-mediated disorders.
BACKGROUND: Obesity stands as an essential factor contributing to infertility in women. Early identification of obese individuals leads to favorable results for female infertility. The objective of this research is to assess the association between the age-adjusted visceral adiposity index (AVAI) and female infertility.
METHODS: This study was conducted using NHANES data from 2013 to 2018, in which 1,231 women aged 20-45 were selected. Infertility was defined by survey questions. AVAI was calculated using anthropometric and serum data. Covariates included demographics and lifestyle factors. Statistical analysis with R, adjusting for covariates, and assessing nonlinearity and cutoff effects.
RESULTS: The study of 1,231 women from the NHANES database revealed that 11.94% were diagnosed with infertility. Individuals with higher AVAI scores showed increased age, WC, BMI, and reduced HDL levels, with a positive correlation between AVAI and female infertility (OR = 1.42, 95%CI: 1.26-1.60). AVAI quartiles showed a pronounced relationship with female infertility risk, with the highest quartile showing the greatest risk(OR = 9.35,95% CI: 2.96-29.55). Nonlinear and threshold effects in the relationship between AVAI and female infertility were identified, with an inflection point at -9.70. Subgroup analyses indicated significant interactions between AVAI and educational status and BMI, particularly in women with a BMI below 25 kg/m2, where a high AVAI level was closely related to increased infertility risk(OR = 1.92, 95%CI: 1.44-2.58).
CONCLUSION: The study identifies a strong association between elevated AVAI scores and female infertility risk, especially in women with a BMI under 25 kg/m2. This suggests that AVAI could be a valuable predictor in female fertility assessments.
Epstein Barr Virus-positive mucocutaneous ulcer (EBVMCU) can be difficult to distinguish from EBV-positive diffuse large B cell lymphoma (DLBCL). We used targeted next-generation sequencing (NGS) to explore genetic alterations in EBVMCU to aid in this diagnostic challenge. Ten cases of EBVMCU were evaluated by a targeted NGS panel of 164 genes. Targeted NGS identified 18 variants in 15 genes in eight cases of EBVMCU. Loss of function TET2 variants were most frequently identified (3 of 10 cases, 30 %). One TET2 variant occurred at low variant allele frequency (VAF) of 3 %, which may be suggestive of clonal hematopoiesis of indeterminate potential. One case harbored a loss of function DNMT3A variant at low VAF. Two cases demonstrated missense variants in the IRF8 gene. Both variants occurred at a VAF close to 50 % and with an estimated high burden of disease (75 %). Two cases of mucosal gastrointestinal involvement had no reportable variants. Mutational profiling of EBVMCU identified TET2 loss of function variants at an elevated frequency in our cohort; however, the findings are not specific and its clinical significance cannot be completely elucidated. Further studies are needed to confirm the findings in an independent and larger cohort of EBVMCU, to determine the cell of origin of the variants, and to further assess their significance in the pathogenesis of this disorder.
AIMS: Doxorubicin is a powerful chemotherapeutic agent for cancer, whose use is limited due to its potential cardiotoxicity. Semaglutide (SEMA), a novel analog of glucagon-like peptide-1 (GLP-1), has received widespread attention for the treatment of diabetes. However, increasing evidence has highlighted its potential therapeutic benefits on cardiac function. Therefore, the objective of this study was to examine the efficacy of semaglutide in ameliorating doxorubicin-induced cardiotoxicity.
METHODS AND RESULTS: Doxorubicin-induced cardiotoxicity is an established model to study cardiac function. Cardiac function was studied by transthoracic echocardiography and invasive hemodynamic monitoring. The results showed that semaglutide significantly ameliorated doxorubicin-induced cardiac dysfunction. RNA sequencing suggested that Bnip3 is the candidate gene that impaired the protective effect of semaglutide in doxorubicin-induced cardiotoxicity. To determine the role of BNIP3 on the effect of semaglutide in doxorubicin-induced cardiotoxicity, BNIP3 with adeno-associated virus serotype 9 (AAV9) expressing cardiac troponin T (cTnT) promoter was injected into tail vein of C57/BL6J mice to overexpress BNIP3, specifically in the heart. Overexpression of BNIP3 prevented the improvement in cardiac function caused by semaglutide. In vitro experiments showed that semaglutide, via PI3K/AKT pathway, reduced BNIP3 expression in the mitochondria, improving mitochondrial function.
CONCLUSION: Semaglutide ameliorates doxorubicin-induced mitochondrial and cardiac dysfunction via PI3K/AKT pathway, by reducing BNIP3 expression in mitochondria. The improvement in mitochondrial function reduces doxorubicin-mediated cardiac injury and improves cardiac function. Therefore, semaglutide is a potential therapy to reduce doxorubicin-induced acute cardiotoxicity.
Placebo Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.